As expected, posterior probabilities of equivalence increased with wider margins across all dose pairs
Gadella (Addgene plasmid no
Sources Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company July 23, 2026 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) National Library of Medicine April 13, 2026 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) National Library of Medicine May 22, 2026,
By suppressing appetite and reducing cravings, these drugs alter the brain's normal reward responses to food
245 Main St, 2nd Floor, Cambridge, MA 02142 U.S.A